Published in Eur J Clin Pharmacol on May 03, 2013
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol (2015) 0.84
Prevalence of Therapeutic Drug Monitoring for Antidepressants and Antipsychotics in Stockholm, Sweden: A Longitudinal Analysis. Ther Drug Monit (2015) 0.78
Arterial blood gas analysis and the outcome of treatment in tricyclic antidepressants poisoned patients with benzodiazepine coingestion. Anesthesiol Res Pract (2015) 0.77
Development of a computerised decisions support system for renal risk drugs targeting primary healthcare. BMJ Open (2015) 0.75
In vivo Raman measurement of levofloxacin lactate in blood using a nanoparticle-coated optical fiber probe. Biomed Opt Express (2016) 0.75
Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman. Saudi Pharm J (2014) 0.75
Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees. Front Pharmacol (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm (2009) 7.43
Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J (1974) 3.42
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother (2008) 3.09
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet (2011) 2.68
Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J (1971) 2.19
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care (2010) 2.11
Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis (2012) 2.06
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med (2012) 2.04
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol (2010) 1.96
Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol (2008) 1.70
Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med (2010) 1.43
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents (2010) 1.43
Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics (1993) 1.16
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol (1994) 1.11
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit (1994) 1.05
Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med (1974) 1.04
Development and practical application of a library of CID accurate mass spectra of more than 2,500 toxic compounds for systematic toxicological analysis by LC-QTOF-MS with data-dependent acquisition. Anal Bioanal Chem (2010) 0.99
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care (2012) 0.99
Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation (2011) 0.94
What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents (2012) 0.89
Indirect plasma-theophylline monitoring in asthmatic children by determination of theophylline concentration in saliva. Pediatrics (1974) 0.88
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis (2013) 0.86
Bioanalytical issues in patient-friendly sampling methods for therapeutic drug monitoring: focus on antiretroviral drugs. Bioanalysis (2009) 0.85
Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem (2007) 0.85
Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother (2007) 0.83
Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit (2011) 0.83
Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin? Ann Intensive Care (2012) 0.82
Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Ther Drug Monit (2004) 0.81
Current technologies and considerations for drug bioanalysis in oral fluid. Bioanalysis (2009) 0.81
The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther (2007) 0.80
Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal Bioanal Chem (2012) 0.80
Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit (2000) 0.78
Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider. Crit Care (2011) 0.77
LC-MS/MS for immunosuppressant therapeutic drug monitoring. Bioanalysis (2010) 0.76
Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy. Eur J Clin Pharmacol (1976) 0.75
Predicting warfarin dose. Curr Opin Pulm Med (2010) 0.75
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther (2006) 3.09
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet (2014) 2.08
Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem (2013) 1.67
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv (2008) 1.63
Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction (2013) 1.62
Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2013) 1.53
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol (2002) 1.52
Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull (2010) 1.45
A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics (2012) 1.42
Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry (2008) 1.42
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. BMJ Open (2012) 1.34
The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv (2008) 1.22
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics (2008) 1.22
Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol (2010) 1.22
Evaluation of a new immunoassay for urinary ethyl glucuronide testing. Alcohol Alcohol (2007) 1.21
Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology (2007) 1.19
Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol (2011) 1.19
Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol (2008) 1.13
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther (2002) 1.09
Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis (2007) 1.09
The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo. J Lipid Res (2009) 1.08
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia (2007) 1.06
Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis. PLoS One (2010) 1.05
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol (2011) 1.04
Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol (2006) 1.03
Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend (2009) 1.02
What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol (2011) 1.00
Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs (2004) 1.00
Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis (2002) 1.00
Ethyl sulfate: a metabolite of ethanol in humans and a potential biomarker of acute alcohol intake. J Anal Toxicol (2005) 0.98
Comparison of urinary excretion characteristics of ethanol and ethyl glucuronide. J Anal Toxicol (2002) 0.96
Method development for routine liquid chromatography-mass spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in blood. Clin Chim Acta (2011) 0.95
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol (2006) 0.95
Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. Liver Transpl (2007) 0.94
Muscle toxicity with statins. Pharmacoepidemiol Drug Saf (2010) 0.93
Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol (2003) 0.92
[STRIDA in the fight against il(legal) Internet drugs]. Lakartidningen (2012) 0.91
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol (2013) 0.91
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol (2015) 0.91
Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol (2003) 0.90
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol (2005) 0.90
Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol (2003) 0.90
Measuring substance use in the club setting: a feasibility study using biochemical markers. Subst Abuse Treat Prev Policy (2012) 0.88
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther (2002) 0.88
Use of morphine and 6-monoacetylmorphine in blood for the evaluation of possible risk factors for sudden death in 192 heroin users. Addiction (2003) 0.87
The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) (2009) 0.87
Mass spectrometric identification of ethyl sulfate as an ethanol metabolite in humans. Clin Chem (2004) 0.86
Patterns of illicit drug use and retention in a methadone program: a longitudinal study. J Opioid Manag (2007) 0.86
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol (2003) 0.86
Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J Anal Toxicol (2005) 0.85
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol (2009) 0.85
Direct quantification of ethyl glucuronide in clinical urine samples by liquid chromatography-mass spectrometry. Ther Drug Monit (2002) 0.84
Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit (2002) 0.84
Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers. J Anal Toxicol (2005) 0.84
Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol (2002) 0.84
Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res (2012) 0.84
Pharmacokinetics of dexamphetamine in acute stroke. Clin Neuropharmacol (2003) 0.84
Pharmacogenetics of anticoagulants. Hum Genomics Proteomics (2010) 0.84
Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol (2002) 0.83
Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet (2009) 0.83
Bioanalytical investigation of asarone in connection with Acorus calamus oil intoxications. J Anal Toxicol (2009) 0.83
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res (2007) 0.83
Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol (2008) 0.83
Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project. Scand J Clin Lab Invest (2013) 0.83
Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol (2013) 0.83
Effect of ceftobiprole on the normal human intestinal microflora. Int J Antimicrob Agents (2010) 0.82
Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain (2002) 0.82
Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics (2009) 0.82
Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. Clin Toxicol (Phila) (2015) 0.82
An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry (2005) 0.82
Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry (2007) 0.82
Multicomponent LC-MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-experience from the Swedish population. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.82
Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. Basic Clin Pharmacol Toxicol (2014) 0.82
Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model. Basic Clin Pharmacol Toxicol (2013) 0.82
CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol (2004) 0.81
ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit (2008) 0.81
Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials. Clin Toxicol (Phila) (2009) 0.81
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients. Hum Psychopharmacol (2010) 0.81
Comparison of analytical approaches for liquid chromatography/mass spectrometry determination of the alcohol biomarker ethyl glucuronide in urine. Rapid Commun Mass Spectrom (2010) 0.81
Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Pharmacogenomics (2014) 0.81
Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl) (2006) 0.81
A multi-component LC-MS/MS method for detection of ten plant-derived psychoactive substances in urine. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.81
Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol (Phila) (2015) 0.80
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol (2010) 0.80
A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate. Alcohol Alcohol (2004) 0.80
Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Rev Pharmacoecon Outcomes Res (2012) 0.80
Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial. Pharmacotherapy (2015) 0.80
Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. Drug Metab Dispos (2013) 0.80
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics (2013) 0.80
Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene. Eur J Clin Pharmacol (2004) 0.80
Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis. Pharmacogenomics (2009) 0.79
Possible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database. Br J Clin Pharmacol (2011) 0.79
Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Appl Health Econ Health Policy (2013) 0.79